3 citations
,
November 2024 in “Clinical Research” Deuruxolitinib is FDA-approved for treating severe alopecia areata.
5 citations
,
January 2021 in “Daru” A woman had severe reactions to methotrexate, including skin issues and organ problems, but improved after 38 days in the hospital.
July 2024 in “Journal of Investigative Dermatology” Brepocitinib reduces interferon signaling in hidradenitis suppurativa patients.
1 citations
,
November 2022 in “Journal of Investigative Dermatology” ALRN-6924 may prevent hair loss caused by chemotherapy.
9 citations
,
November 2018 in “Acta Clinica Belgica” Don't combine abiraterone and spironolactone for prostate cancer treatment as it may worsen the disease.
8 citations
,
January 1996 in “Gynecological Endocrinology” Cyproterone acetate is the preferred treatment for women's hyperandrogenism when estrogen/progestogen use is safe.
39 citations
,
November 2015 in “Pediatric Nephrology” Rituximab leads to longer remission and fewer side effects than cyclophosphamide.
January 2010 in “DOAJ (DOAJ: Directory of Open Access Journals)” IV cyclophosphamide effectively treated severe lupus nephritis in Indian patients, but longer follow-up is needed.
1 citations
,
March 2022 in “JAAD case reports” Methotrexate injection site reactions are rare but can be managed by changing injection sites and using topical treatments.
84 citations
,
August 2023 in “Drugs” Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.
4 citations
,
November 2021 in “Journal of The American Academy of Dermatology” Bicalutamide may reduce unwanted hair growth caused by minoxidil in women with hair loss.
1 citations
,
December 1970 in “European journal of endocrinology” Reversed sequential therapy with cyproterone acetate was effective for treating women with hirsutism and related conditions.
49 citations
,
April 1997 in “Human reproduction” Hormone therapy for excessive hair growth is as good with GnRHa as with high-dose CPA, but GnRHa has longer-lasting results.
January 1983 in “Elsevier eBooks” Cyproterone acetate is used to treat conditions like prostate cancer, early puberty, excessive sexual drive, and female androgenization by affecting androgen functions and suppressing certain hormones.
April 2017 in “Journal of Investigative Dermatology” Triptolide effectively and safely reduces actinic keratosis lesions in mice.
January 2004 in “Drug Development and Industrial Pharmacy” GI197111X is best dissolved in Capmul MCM for trials.
1 citations
,
July 2024 in “Journal of Investigative Dermatology” TAK-279 effectively reduces psoriasis symptoms and is safe.
1 citations
,
January 2007 in “The Kitakanto Medical Journal” Effective treatment for UFT overdose includes antibiotics and G-CSF, with bone marrow biopsy and transfusion as backup options.
9 citations
,
April 2015 in “Dermatologic Therapy” Hormonal therapies, like flutamide and cyproterone acetate, are safe and effective for treating adult women's acne, especially those with hormone imbalance or resistant acne.
PLX, a tomato extract mix, may help treat prostate issues like BPH.
April 2019 in “Journal of the Endocrine Society” Rapid virilization should be checked for possible ovarian or adrenal cancer.
January 2025 in “JCEM Case Reports” Metyrapone can effectively treat Cushing's Disease even if the mass causing it is not found.
2 citations
,
January 2014 in “Advanced Biomedical Research” Oral isotretinoin and cyproterone compound are equally effective for treating acne in women with cutaneous hyperandrogenism.
June 2019 in “Reactions Weekly”
4 citations
,
December 1994 in “PubMed” Cyproterone acetate with estradiol improved women's self-confidence and emotional well-being without a difference between oral or transdermal methods, but younger women preferred the oral method.
June 2021 in “SWU eJournals System (Srinakharinwirot University)” Mixed coconut oil/solvent is suitable for cyproterone acetate injections, but more safety checks are needed.
April 2026 in “Clinical Journal of Gastroenterology” Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.
9 citations
,
July 2017 in “Journal of medical case reports” Ruxolitinib treatment may cause eyelash growth.
February 2026 in “Toxicology Letters” MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.
November 2024 in “Nanomaterials” The nanocrystalline suspension effectively delivers dutasteride over time with minimal inflammation.